BACKGROUND: 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis has been used as an inflammatory bowel disease (IBD), Crohn's disease (CD), preclinical model. However, published data on pharmacologic and therapeutic efficacy testing of this model are limited. FTY720 inhibits lymphoid cell trafficking in inflammatory conditions and is of interest to treat IBD. AIM: We investigated the pharmacologic therapeutic efficacy of sulfasalazine, FTY720, and anti-IL-12/23p40, in a TNBS CD model. METHODS: Female, 7-week-old, BALB/c mice were given sulfasalazine orally (PO) and intraperitoneally (IP) at 10 mg/kg, FTY720 at 3 mg/kg PO, and mouse anti-IL-12/23p40 at 25 mg/kg IP. Vehicle groups given PO either phosphate-buffered saline/water or 40% ethanol served as controls. Pharmacologic efficacy was assessed using body weight loss, clinical scores of diarrhea and intestinal gross pathology, and colon weight parameters. RESULTS: Sulfasalazine and FTY720 treatment did not prevent body weight loss or reduce clinical scores of diarrhea or intestinal gross pathology, when compared with vehicle treatment. However, anti-IL-12/23p40 treatment showed significant efficacy by preventing body weight loss, reducing clinical scores of diarrhea, and reducing intestinal gross pathologic lesions, when compared with vehicle-treated animals. Sulfasalazine, anti-IL-12/23p40, and FTY720 were not effective in reducing colon weight. CONCLUSION: With the exception of anti-IL-12/23p40, sulfasalazine, and FTY720 did not demonstrate full pharmacologic efficacy in our TNBS CD model.
BACKGROUND:2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis has been used as an inflammatory bowel disease (IBD), Crohn's disease (CD), preclinical model. However, published data on pharmacologic and therapeutic efficacy testing of this model are limited. FTY720 inhibits lymphoid cell trafficking in inflammatory conditions and is of interest to treat IBD. AIM: We investigated the pharmacologic therapeutic efficacy of sulfasalazine, FTY720, and anti-IL-12/23p40, in a TNBS CD model. METHODS: Female, 7-week-old, BALB/c mice were given sulfasalazine orally (PO) and intraperitoneally (IP) at 10 mg/kg, FTY720 at 3 mg/kg PO, and mouse anti-IL-12/23p40 at 25 mg/kg IP. Vehicle groups given PO either phosphate-buffered saline/water or 40% ethanol served as controls. Pharmacologic efficacy was assessed using body weight loss, clinical scores of diarrhea and intestinal gross pathology, and colon weight parameters. RESULTS:Sulfasalazine and FTY720 treatment did not prevent body weight loss or reduce clinical scores of diarrhea or intestinal gross pathology, when compared with vehicle treatment. However, anti-IL-12/23p40 treatment showed significant efficacy by preventing body weight loss, reducing clinical scores of diarrhea, and reducing intestinal gross pathologic lesions, when compared with vehicle-treated animals. Sulfasalazine, anti-IL-12/23p40, and FTY720 were not effective in reducing colon weight. CONCLUSION: With the exception of anti-IL-12/23p40, sulfasalazine, and FTY720 did not demonstrate full pharmacologic efficacy in our TNBS CD model.
Authors: C O Elson; K W Beagley; A T Sharmanov; K Fujihashi; H Kiyono; G S Tennyson; Y Cong; C A Black; B W Ridwan; J R McGhee Journal: J Immunol Date: 1996-09-01 Impact factor: 5.422
Authors: Anthony T Cao; Suxia Yao; Andrew T Stefka; Zhanju Liu; Hongwei Qin; Houpu Liu; Heather L Evans-Marin; Charles O Elson; Cathryn R Nagler; Yingzi Cong Journal: J Leukoc Biol Date: 2014-07-11 Impact factor: 4.962
Authors: Lise Verbruggen; Lindsay Sprimont; Eduard Bentea; Pauline Janssen; Azzedine Gharib; Lauren Deneyer; Laura De Pauw; Olaya Lara; Hideyo Sato; Charles Nicaise; Ann Massie Journal: Front Pharmacol Date: 2021-05-18 Impact factor: 5.810
Authors: T Karuppuchamy; E-H Behrens; P González-Cabrera; G Sarkisyan; L Gima; J D Boyer; G Bamias; P Jedlicka; M Veny; D Clark; R Peach; F Scott; H Rosen; J Rivera-Nieves Journal: Mucosal Immunol Date: 2016-04-06 Impact factor: 7.313